HOW DOES OUR hhc
MISSION INSPIRE ONCOLOGY BREAKTHROUGHS? HERE’S A REAL-WORLD EXAMPLE
When we first set out to develop a new anti-cancer agent, we
didn’t sacrifice quality for speed. We concentrated on
diseases with poor prognoses and few treatment options,
regardless of the size of the patient populations. We
prioritized how the compound would bind to certain targets
implicated in the pathogenesis of the cancer.
Our determination to address patients' unmet medical needs
drove us to synthesize a chemical process with millions of
steps. Ultimately, it led us to develop a targeted agent.
We're now investigating that agent with Merck (known as MSD outside the United States and Canada) in combination with their anti-PD-1 therapy in different kinds of cancer in the hopes of reaching more patients in need. In fact, Eisai and Merck received two Breakthrough Therapy designations and two approvals from the FDA.
We're evaluating the combination in 13 tumor types across 20 clinical trials:
Biliary tract cancer
Non-small cell lung cancer
Renal cell carcinoma
Squamous cell carcinoma of the head and neck
Learn more about our collaboration
Learn more about: